A 12-Month Multicentre, Randomised, Double-Blind, Placebo-Controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors
Latest Information Update: 12 Apr 2022
Price :
$35 *
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Acronyms RIALTO
- Sponsors Sanofi
- 08 Apr 2022 This trial has been completed (End Date: 29 Jan 2009), according to European Clinical Trials Database record.
- 07 Jul 2009 Actual patient number (174) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Additional trial acronym RIALTO identified as reported by ClinicalTrials.gov.